Aquilano D R, Tsai-Morris C H, Hattori M A, Dufau M L
Endocrinology. 1985 May;116(5):1745-54. doi: 10.1210/endo-116-5-1745.
In order to define the early lesion (before pregnenolone formation) of the androgen biosynthetic pathway induced by human CG (hCG) or LH in the Leydig cell, we initially have optimized the use of aminoglutethimide to obtain maximal and sustained inhibition of steroidogenesis in vivo and in vitro. Aminoglutethimide inhibited Leydig cell steroidogenesis in vitro at a dose of 100 micrograms/ml. The minimal serum concentration of aminoglutethimide necessary for maximal inhibition of testosterone in vivo was also 100 micrograms/ml (1 h after the ip injection of 20 mg aminoglutethimide). However, testosterone levels were normal 12 h later, coincident with a marked fall in the serum aminoglutethimide levels. The t 1/2 of the circulating aminoglutethimide was 5 +/- 0.7 h on the first day of treatment but was reduced to 3.0 +/- 0.4 and 2.25 +/- 0.35 h at 2 and 3 days of treatment. At the dose eliciting maximal and sustained steroid inhibition (60 mg/day) aminoglutethimide was able to prevent the estradiol-dependent late steroidogenic lesion (after pregnenolone formation) induced by 1 microgram hCG, with no effect on the early lesion (before pregnenolone formation) caused by 10 micrograms hCG. The aminoglutethimide-induced in vivo accumulation of cholesterol in the inner mitochondrial membrane (by 50%) was associated with an increase in the production of testosterone and pregnenolone by the Leydig cell when subsequently incubated in vitro. Similar increases in the steroidogenic capacity were observed after initial exposure of Leydig cells to aminoglutethimide in vitro, even after acid wash to remove the surface-bound endogenous LH. The steroidogenic cholesterol was also increased in desensitized Leydig cells (by 50-70%); however, the conversion of cholesterol to pregnenolone was substantially blocked in animals with the early lesion. Our findings define the requirement of increasing high levels of aminoglutethimide to inhibit cholesterol metabolism and provide a dose schedule suitable for studies on cholesterol availability and inhibition of steroidogenesis in the rat. These results support our proposal that the early lesion observed in desensitized Leydig cells is due to inhibition of the side-chain cleavage activity rather than to a decrease in the amount of metabolically available cholesterol.
为了明确人绒毛膜促性腺激素(hCG)或促黄体生成素(LH)诱导的睾丸间质细胞雄激素生物合成途径的早期病变(在孕烯醇酮形成之前),我们首先优化了氨鲁米特的使用方法,以在体内和体外获得对类固醇生成的最大且持续的抑制作用。氨鲁米特在体外以100微克/毫升的剂量抑制睾丸间质细胞类固醇生成。体内最大程度抑制睾酮所需的氨鲁米特的最低血清浓度也是100微克/毫升(腹腔注射20毫克氨鲁米特后1小时)。然而,12小时后睾酮水平恢复正常,与此同时血清氨鲁米特水平显著下降。治疗第一天循环中的氨鲁米特的半衰期为5±0.7小时,但在治疗第2天和第3天分别降至3.0±0.4小时和2.25±0.35小时。在引起最大且持续的类固醇抑制作用的剂量(60毫克/天)下,氨鲁米特能够预防由1微克hCG诱导的雌二醇依赖性晚期类固醇生成病变(在孕烯醇酮形成之后),而对由10微克hCG引起的早期病变(在孕烯醇酮形成之前)没有影响。氨鲁米特在体内诱导线粒体内膜中胆固醇蓄积(增加50%),这与随后在体外培养时睾丸间质细胞睾酮和孕烯醇酮生成增加相关。在体外将睾丸间质细胞最初暴露于氨鲁米特后,即使经过酸洗以去除表面结合的内源性LH,也观察到类固醇生成能力有类似增加。脱敏的睾丸间质细胞中类固醇生成胆固醇也增加(50% - 70%);然而,在有早期病变的动物中,胆固醇向孕烯醇酮的转化被显著阻断。我们的研究结果明确了需要提高氨鲁米特水平以抑制胆固醇代谢,并提供了一个适用于研究大鼠胆固醇可用性和类固醇生成抑制的剂量方案。这些结果支持了我们的观点,即脱敏的睾丸间质细胞中观察到的早期病变是由于侧链裂解活性受到抑制,而非代谢可用胆固醇量减少。